Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy by Farahnak, P et al.
CLINICAL STUDY
Cardiac function in mild primary hyperparathyroidism and
the outcome after parathyroidectomy
P Farahnak, M Ring
1, K Caidahl
1, L-O Farnebo
2, M J Eriksson
1 and I-L Nilsson
2
Section of Surgery, Department of Clinical Science and Education, Karolinska Institutet So ¨dersjukhuset, S-118 83 Stockholm, Sweden,
1Section of Clinical
Physiology and
2Section of Endocrine Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital,
SE-17176 Stockholm, Sweden
(Correspondence should be addressed to P Farahnak; Email: parastou.farahnak@ki.se)
Abstract
Objective: Primary hyperparathyroidism (PHPT) is associated with cardiovascular morbidity. The
extent of cardiovascular abnormalities in patients with mild-asymptomatic disease is unclear. Using
sensitive echocardiographic methods, we compared cardiac structure and function in patients with
mild PHPT and in healthy controls, and evaluated the changes after parathyroidectomy (PTX).
Methods: In a prospective case–control design, we studied 51 PHPT patients without any
cardiovascular risk factors/diseases and 51 healthy matched controls. Cardiac structure, and systolic
and diastolic function were evaluated by echocardiography and Doppler tissue imaging (DTI). Blood
pressure (BP) and heart rate were measured.
Results: We observed no differences in systolic or diastolic function or in cardiac morphology between
the PHPT patients and the age-matched healthy controls. The regional peak systolic myocardial
velocities (S0) measured with DTI decreased at all sites (P!0.05) after PTX (tricuspid annulus
14.23G1.85 to 13.48G1.79, septal 8.48G0.96 to 7.97G0.85, and lateral 9.61G2.05 to
8.87G1.63 cm/s, part of the mitral annulus). At baseline, systolic BP was higher in patients
compared to controls (127.6G17.1 vs 119.6G12.6 mmHg, P!0.05). After PTX, both systolic
(127.6G17.1 vs 124.6G16.6 mmHg, P!0.05) and diastolic (80.3G9.6 vs 78.4G8.6 mmHg,
P!0.05) BP decreased.
Conclusions: Our results indicate that patients with PHPT without cardiovascular risk factors have a
normal global systolic and diastolic function and cardiac morphology. BP and the systolic velocities
were marginally reduced after PTX, but reﬂected the values of the control group. Our ﬁndings warrant
further investigation of the clinical and prognostic signiﬁcance of these possibly disease-related
inotropic effects.
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Introduction
Primary hyperparathyroidism (PHPT) is a common
endocrine disorder; in most cases, it is caused by a
solitary parathyroid adenoma (1). The prevalence is
highest in postmenopausal women, i.e. 3–4% (2).I n
recent decades, the clinical proﬁle has shifted towards a
less marked symptomatology. Today, the majority of
patients with newly diagnosed PHPT show none of the
classic symptoms or signs traditionally associated with
the disease. The only cure for PHPT is surgical removal
of the abnormal parathyroid gland/glands. Although
most experts agree that all patients with so-called
classic symptoms of PHPT should be offered parathy-
roidectomy (PTX), there is still a controversy about
which patients can be handled conservatively (3).
PHPT has been associated with increased cardiovas-
cular mortality and morbidity. Some of the reported
abnormalities are diastolic myocardial dysfunction, left
ventricular hypertrophy, hypertension, autonomic
imbalance, metabolic disturbances and endothelial
vasodilatory dysfunction with varying normalization
after PTX (4–11). However, the extent and clinical
signiﬁcance of cardiovascular risk factors coupled to
PHPT are matters for discussion. Conﬂicting data have
been reported on the incidence of cardiovascular
disorders in mild PHPT (12–15). It has been argued
that the risk of cardiovascular complications is coupled
to more severe disease (16).O u rk n o w l e d g eo f
cardiovascular abnormalities in PHPT is mostly based
on data from cohorts that include patients with
pre-existing cardiovascular risk factors or diseases that
may confound the results. The aim of our study was
to evaluate cardiac structure and function using
echocardiography and Doppler tissue imaging (DTI) in
patients with mild PHPT, without cardiovascular risk
factors, before and after PTX and in comparison to
healthy controls.
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Study design
Analysis was carried out by the intention-to-treat
method in a prospective study design. Patients and
controls underwent blood analyses, echocardiography,
and DTI at baseline, and the patients were re-examined
a mean of 15G4 months after successful PTX.
Subjects
The patient population was consecutively recruited
from the referrals for parathyroid surgery due to PHPT
at the Karolinska University Hospital in Stockholm,
Sweden, between January 2006 and November 2008.
During the study period, a total of 410 PHPT patients
(319 women) were treated with PTX at the clinic. The
following inclusion criteria were used: patients with
PHPT who fulﬁlled the criteria for PTX, no history of
cardiovascular diseases or any other disease known to
affect the cardiovascular system, no medication affect-
ing the cardiovascular system, no diabetes mellitus or
renal diseases, no arterial hypertension (deﬁned as
systolic blood pressure (SBP) O140 mmHg and
diastolic blood pressure (DBP) O90 mmHg), body
mass index (BMI) !28, and age O18 and !70 years.
Fifty-three patients met the inclusion criteria. After
inclusion, two patients were excluded from the study.
One woman regretted her decision to undergo PTX. One
man underwent parathyroid exploration with the
ﬁnding of normal parathyroids; later, mutation analysis
veriﬁed the diagnosis of familial hypocalciuric hyper-
calcemia. A majority of the patients had no overt
symptoms or signs associated with PHPT; except for a
history of kidney stone disease (nZ9) and bone mineral
density below K2.5 at any site (nZ6). The healthy
control group (age- and gender-matched) was randomly
selected from the population registry of the city of
Stockholm. They were asked to participate in the study
by mail and included if they fulﬁlled the inclusion
criteria described above. Two controls were replaced
before entering the study, one because of a high
P-parathyroid hormone (PTH) level and the other
because of hypertension. Finally, 51 patients and 51
controls (16 men and 35 women) were included in the
study. Fifty patients were re-examined with echocardio-
graphy and DTI after a mean follow-up time of 15G4
months (range 7–28 months); one woman only
participated in the blood analyses at follow-up. BMI
was calculated by dividing weight (kg) by the square of
height (m). Body surface area (BSA) was calculated
by the following formula: BSAZ(0.0001)!(71.84)
!(weight)
0.425!(height)
0.725, where weight was
measured in kilograms and height in centimetres.
Each subject gave written consent to participate in
the study, which was approved by the ethics committee
of the Karolinska Institute in Stockholm, Sweden.
Laboratory methods
Biochemical variables were estimated after an overnight
fast by anaerobic sampling before and 15G4 months
afterPTX.Clinicalroutinemethodswereusedtoestimate
thevaluesfor totalplasmacalcium,albumin,creatinine,
glucose, phosphate, TSH (Synchron LXw 20 system,
Beckman Coulter Inc., Brea, CA, USA), serum-ionized
calcium (Ca
CC) (ABL 800, Radiometer, Copenhagen,
Denmark), intact plasma PTH (electrochemilumines-
cense immunoassay on the Modular E system, Roche
Diagnostics GmbH, Mannheim, Germany), and pro-brain
natriuretic peptide (NT-pro-BNP).
Blood pressure
Blood pressure (BP) was measured in both arms after
at least 30 min of rest, using an appropriately sized
cuff and automatic monitor (Digital Automatic
Blood Pressure Monitor, Omron Healthcare Kyoto,
Japan). The mean values of systolic and diastolic
pressure in the two arms were calculated, and heart
rate was noted.
Echocardiography
All examinations were performed by one experienced
echocardiographer, using an ultrasound scanner Vivid 7
(General Electric, Horten, Norway) equipped with DTI
capabilities. The patients were placed in the left lateral
recumbent position, and the two-dimensional, M-mode,
and Doppler echocardiography was performed in accord-
ance with the guidelines of the American Society of
Echocardiography (17). All images were stored digitally
on an ultrasound database Echopac. Standard echocardio-
graphic measurements included right ventricular
end-diastolic diameter, left ventricular (LV) end-diastolic
diameter (LVDd) and end-systolic diameter (LVDs), end-
diastolic interventricular septum thickness (IVSd), and
left ventricular posterior wall thickness (PWTd). The
fractional shortening (FS %), ejection fraction (EF %),
and atrioventricular plane (AV-plane) displacement
were calculated from M-mode recordings. LV mass was
calculated by the following formula: LVM (grams)Z0.8
(1.05 ((LVDdCIVSdCPWTd)
3K(LVDd)
3)) (18). The LV
mass was divided by BSA to calculate the LV mass index
(LVMI). The cut-off points for LV hypertrophy (LVH)
using the LVM/BSA ratio were 150 g/m
2 for males and
120 g/m
2 for females (19). Relative wall thickness
(RWT) was calculated according to the following
formula: RTWZ(IVSCPWT)/LVDd. From the calcu-
lation of RWT, two geometric patterns of LVH could be
established as follows: a concentric pattern, when RWT
was R0.42, and an eccentric pattern, when RWT
%0.42 (17). Transmitral inﬂowand pulmonary venous
ﬂow velocities were acquired with pulsed wave Doppler.
The velocities of early transmitral diastolic ﬂow (E) and
ﬂowvelocityduringatrialcontraction(A),itsratio(E/A),
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(IVRT) were measured. The maximal left atrial area was
traced at end systole in a four-chamber view.
Doppler tissue imaging
Pulsed Doppler DTI was recorded in the apical
four-chamber view at three sites: the tricuspid annulus
for the right ventricle (RV) and in the septal and lateral
parts of the mitral annulus for the left ventricle (LV).
A 3 mm sampling volume was used. Peak systolic (S0),
early diastolic (E0), and late diastolic (A0) velocities
recorded by DTI were measured. E0/A0 and E/E0 for
the septal and the lateral part of the mitral annulus
were calculated.
Image analyses
All variables describing cardiac dimensions and
structure were analyzed off-line by one observer
unaware of the patient’s status. The remaining
Doppler-derived variables were analyzed by another
observer. All measurements were averaged from at least
three heartbeats. To assess the measurement variability,
the two observers re-measured 20 randomly selected
echocardiographic and DTI examinations. The coefﬁ-
cient of variation (CV) was calculated for variables for
the determination of inter- and intra-observer variabil-
ities. CV was calculated as the mean percent error,
deﬁned as the standard error of the absolute difference
between the two sets of measurements, divided by the
mean of the two measurements.
Table 1 Clinical and biochemical data (meanGS.D.) for healthy controls and for patients with primary hyperparathyroidism (PHPT) before
and 15G4 months after parathyroidectomy.
PHPT cases P
Variable
Controls
nZ51
Baseline
nZ51
(35 females)
Follow-up
nZ51
(35 females)
PHPT baseline
versus controls
PHPT baseline
versus follow-up
Age (years) 55.2G8.9 54.3G8.8 55.6G8.7
BMI (kg/m
2) 23.4G2.1 24.1G2.9 24.7G3.2 NS !0.05
BSA 1.78G0.17 1.83G0.18 1.85G0.18 NS !0.05
Ionized C-calcium (mM/l) 1.25G0.04 1.46G0.07 1.25G0.05 !0.001 !0.001
P-Calcium (mM/l) 2.29G0.08 2.62G0.13 2.28G0.08 !0.001 !0.001
P-Albumin (g/l) 38.4G2.6 39.4G2.5 38.5G2.9 !0.05 !0.05
fP-PTH (ng/l) 44.1G12.4 122.6G43.6 48.8G15.2 !0.001 !0.001
P-Phosphate (mM/l) 1.1G0.2 0.84G0.2 1.0G0.2 !0.001 !0.001
P-Creatinine (mM/l) 69.7G13.7 67.3G12.6 69.1G16.6
a NS NS
fP-Glucose (mM/l) 5.0G0.35 5.0G0.44
a 5.0G0.51 NS NS
P-NT-pro-BNP (ng/l) 60.4G35.3
a 63.9G55.1
a 62.8G50.2
a NS NS
BMI, body mass index; BSA, body surface area.
anZ47–49.
Table 2 Blood pressure and echocardiographic variables (meanGS.D.) in the study groups.
PHPT cases P
Controls
nZ51
Baseline
nZ51
(35 females)
Follow-up
nZ50
(34 females)
PHPT baseline
versus controls
PHPT baseline
versus follow-up
BP at rest, systolic (mmHg) 119.6G12.6 127.6G17.1 124.6G16.6 !0.05 !0.05
BP at rest, diastolic (mmHg) 76.1G7.7 80.3G9.6 78.4G8.6 NS !0.05
Heart rate at rest (per min) 61G96 2 G10 60G9N S N S
RVDd (cm) 2.77G0.41 2.70G0.36 2.77G0.36 NS NS
LVDd (cm) 4.89G0.41 4.94G0.40 4.94G0.40 NS NS
LVDs (cm) 3.12G0.40 3.12G0.37 3.15G0.33 NS NS
Left atrial area (cm
2) 19.20G2.80 19.91G3.08 19.94G2.55 NS NS
IVS (cm) 0.91G0.13 0.94G0.16 0.96G0.15 NS NS
PWT (cm) 0.86G0.16 0.88G0.11 0.86G0.13 NS NS
RWT (cm) 0.36G0.05 0.37G0.05 0.37G0.05 NS NS
LVMI (g/m
2)
Males 93.7G11.7 99.3G18.4 98.4G16.0 NS NS
Females 80.6G20.1 81.8G12.3 80.4G14.8 NS NS
BP, blood pressure; RVDd, right ventricular end-diastolic dimension; LVDd, left ventricular end-diastolic dimension; LVDs, left ventricular end-systolic
dimension; IVS, interventricular septum thickness; PWT, left ventricular posterior wall thickness; RWT, relative wall thickness; LVM, left ventricular mass;
LVMI, left ventricular mass index.
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3–4% for inter-observer and 2–3% for intra-observer
analyses. The CV for transmitral ﬂow velocities were
2–4% for inter-observer and 1–2% for intra-observer.
The CV for M-mode AV-plane displacement was 2–4%
for inter-observer and 2–3% for intra-observer analyses.
Statistical analysis
The sample size was based on differences and S.D.o f
diastolic function from earlier studies to guarantee a
power level of 80% at a conﬁdence level of 95% (20, 21).
Statistical analysis was performed with the SPSS for
Windows statistical package 17.0 (SPSS Inc., Chicago,
IL, USA). Data are expressed as meanGS.D. Comparisons
between the group of patients at baseline and the
control group were performed with the Mann–Whitney
U test for unpaired data. Wilcoxon signed rank sum test
was used for intra-individual analyses. Relationships
between variables were assessed with Spearman’s r
correlation test. All tests were done two-tailed, and
P!0.05 was considered to be statistically signiﬁcant.
Results
Clinical and biochemical results
Forty-eight patients had a single parathyroid adenoma
removed; three patients had multiglandular disease.
Normocalcemia was achieved in 49 of 51 patients after
the ﬁrst PTX; the other two patients became normo-
calcemic after a second operation when a second
parathyroid adenoma and an intrathyroidal adenoma
respectively were removed. All patients were normocal-
cemic at the postoperative follow-up 1 month after PTX
(not shown). There were no PTX-related complications.
The mean total wet weight of the excised abnormal
parathyroidtissuewas619G837 mg.Thepatientswere
re-examined a mean of 15G4 (median 14.8) months
after successful PTX. Three patients were re-examined
!1 year after surgery (7, 10, and 11 months
respectively). At the follow-up, PTH levels were slightly
elevated(mean78G9 ng/l)incombinationwithnormal
serumcalcium(meanCa
CC1.24G0.04 mM/l)inseven
cases. Ca
CC was elevated in two cases (one woman on
vitamin D treatment with 1.45 mM/l Ca
CC and 37 ng/l
PTHinwhomCa
CCnormalizedafterdiscontinuationof
vitamin D and another woman with 1.36 mM/l Ca
CC
and 62 ng/l PTH). Clinical and biochemical data of
patients and controls are given at baseline and after PTX
in Table 1. Plasma-intact PTH, calcium, and serum
Ca
CC were signiﬁcantly higher in patients at baseline
compared to healthy controls, while plasma phosphate
levels were signiﬁcantly lower (Table 1). PTH, calcium,
and phosphate concentrations normalized after PTX
and did not differ from controls at the follow-up visit
(Table1).AllsubjectsfulﬁlledtheBPcriteria(SBP%140
and DBP %90 mmHg) before inclusion. At baseline
measurements, SBP was O140 mmHg in 11 patients
and 4 controls (range of all subjects is 180–95 mmHg),
and DBP was O90 mmHg in 9 patients (range of all
subjectsis110–55 mmHg).SBPwassigniﬁcantlyhigher
in the PHPT group compared to controls and decreased
after PTX (Table 2). SBP correlated to the age (rZ0.45;
P!0.001) as well as to the levels of PTH (rZ0.26;
P!0.01,Fig.1a)andCa
CC(rZ0.25;P!0.05,Fig.1b).
DBP decreased after PTX (Table 2).
BMI increased after PTX only in female PHPT
(23.5G2.7 vs 24.3G3.3 kg/m
2, P!0.01), but not in
male PHPT (25.3G3.0 vs 25.6G3.7 kg/m
2, PZNS). In
female PHPT, the weight of the excised abnormal
parathyroid tissue correlated to the PTH but not to
Ca
CC (rZ0.52; P!0.001). Among men, there was a
strong correlation between adenoma weight and Ca
CC
(rZ0.89; P!0.01) but not to PTH. The phosphate level
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Figure 1 Systolic blood pressure for the whole group of PHPT
patients and the healthy control subjects was correlated to (a) the
PTH level (rZ0.26; P!0.01) and to (b) the ionized calcium level
(rZ0.25; P!0.05).
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higher in the female group of PHPT compared to male
PHPT patients.
Echocardiographic results
There were no differences between the groups in the
variables describing cardiac dimensions and structure
(Table 2). The systolic and diastolic LV function
evaluated by Doppler echocardiography was within
normal limits, and there were no differences between
the groups at baseline (Table 3). The regional peak
systolic myocardial velocities (S0) measured with DTI
in the base of the RVs and LVs decreased after PTX
(Table 3). For variables with a signiﬁcant change after
PTX, we also tested post-PTX results for possible
differences compared to the control group. Compared
to our age- and gender-matched healthy controls, the
PHPT group had numerically lower peak systolic
velocities after PTX, but the difference reached a
statistical signiﬁcance only in the lateral part of the
mitral annulus (Table 3). For comparison, previously
publishednormalvaluesforDTImyocardialvelocitiesfor
RVs and LVs are shown in Table 3 (22, 23). The values
are in the same range as in our healthy control group.
The peak systolic velocity of the septal part of the
mitral annulus correlated signiﬁcantly and positively to
the Ca
CC level (rZ0.4; P!0.05) in the PHPT group at
baseline. IVRT was increased in the male PHPT group
compared to female PHPT and the healthy controls
(97G20 vs 82G15, 84G13, P!0.05). The E/A ratio
was inversely correlated to the PTH level (rZK0.33;
P!0.01), SBP (rZK0.40; P!0.01), and DBP
(rZK0.46; P!0.01).
Discussion
The present study was conducted to evaluate cardiac
functionandtheeffectofPTXinpatientswithmildPHPT.
The main strength of our study is the strict design,
excluding PHPT patients with known cardiovascular
risk factors. The PHPT patients included in this study
madeupaboutone-tenthofallthePHPTpatientstreated
with PTXatourclinicduring thetimeperiod. Menmade
up 31% of our study cohort compared with 22% of our
unselected control cohort. We observed no differences
in global systolic or diastolic function, or cardiac
morphology, in our PHPT patients compared to the
age-matchedhealthycontrols.Theregionalpeaksystolic
myocardial velocities in the RVs and LVs in our
study correspond to normal values described previously
(22, 23). However, the PHPT patients did show a
signiﬁcant decrease in BP and regional peak systolic
myocardial velocities after PTX. In one site, the regional
peak systolic myocardial velocities were signiﬁcantly
lowerinpatientsafterPTXcomparedtohealthycontrols.
Our results indicate that patients with mild PHPT
without any other known cardiovascular risk factors
Table 3 Systolic and diastolic function variables (meanGS.D.) by echocardiography and Doppler tissue imaging at baseline and follow-up.
The values are meanGS.D.
PHPT cases P
Variable
Controls
nZ51
Baseline
nZ51
(35 females)
Follow-up
nZ50
(34 females)
PHPT baseline
versus controls
PHPT baseline
versus follow-up
Systolic variable
DTI-RV systolic velocity (cm/s) (13.5G1.7)
a 13.85G1.77 14.23G1.85 13.48G1.79 NS !0.05
DTI-IVS systolic velocity (cm/s) (7.7G1.7)
b 8.23G1.00 8.48G0.96 7.97G0.85 NS !0.05
DTI-LVL systolic velocity (cm/s) (8.5G2.2)
b 9.80G1.89 9.61G2.05 8.87G1.63* NS !0.05
Ejection fraction (%) 65.29G6.17
c 66.18G5.78
c 65.75G4.84
c NS NS
Fractional shortening (%) 36.29G5.14
c 37.02G4.33
c 36.46G3.81
c NS NS
AV-plane RV (cm) 2.64G0.32 2.58G0.37 2.50G0.39 NS NS
AV-plane IVS (cm) 1.44G0.20 1.42G0.18 1.39G0.19 NS NS
AV-plane LV (cm) 1.57G0.21 1.55G0.18 1.55G0.18 NS NS
Diastolic variable
E-wave (cm/s) 80.18G14.44 75.76G15.09 75.77G13.47 NS NS
A-wave (cm/s) 59.59G12.48 60.58G15.27 61.41G12.70 NS NS
E/A 1.39G0.33 1.30G0.34 1.27G0.28 NS NS
DT (ms) 197.9G22.6 199.7G27.9 200.8G29.3 NS NS
Isovolumic relaxation time (ms) 82.36G16.20 86.67G18.42 86.32G19.42 NS NS
PVs/PVd 1.16G0.27 1.22G0.34 1.21G0.32 NS NS
E/E0 Septal 7.81G1.73 7.69G1.74 7.54G1.58 NS NS
E/E0 Lateral 6.38G1.43 6.35G1.84 6.50G1.61 NS NS
DTI, Doppler tissue imaging; AV-plane, atrioventricular plane displacement; RV, right ventricular wall; LVL, left ventricular lateral wall; IVS, interventricular
septum; E-wave, early transmitral diastolic ﬂow velocity; A-wave, ﬂow velocity during atrial contraction; DT, deceleration time; PVs, systolic pulmonary vein
velocity; PVd, diastolic pulmonary vein velocity; E/E0, a ratio of early transmitral diastolic ﬂow velocity (E) and early diastolic velocity recorded by DTI (E0)i nt h e
mitral annulus. *The peak systolic velocity in the lateral part of the mitral annulus was lower in patients after PTX compared to controls, P!0.05.
aIndicates the reference for published DTI values for RV (22).
bIndicates the reference for published DTI values for LV (23).
cnZ49–50.
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baseline, which seems to be associated with the level of
PTH and Ca
CC. The clinical signiﬁcance of these
ﬁndings is not clear. Hypothetically, a disease-related
inotropic effect may result in increased vascular
resistance and in an increased cardiac workload. Our
hypothesis is supported by the results of a study that
compared patients with mild PHPT randomized to PTX
either directlyor after 1 year of observation (24). In that
study, some of the systolic and diastolic function
parameters decreased after PTX when the PTH and
calcium levels had normalized. The functional changes
observed were transient, and the values in question
returned to preoperative levels within 1 year. This
reaction pattern was interpreted as a withdrawal
inotropic effect of PTH. The authors also found higher
LVMI in the group of patients followed without surgery,
and the extent of the LVMI increase was associated with
PTH. These ﬁndings support our hypothesis of a supra-
systolic performance that may promote cardiac hyper-
trophy and morbidity. Cook et al. (25) concluded, from a
longitudinal cohort study, that a small reduction of
2 mmHginDBPinthepopulation,inadditiontomedical
treatment, could have a major public health impact on
the risk of coronary heart disease and of stroke events.
Only a few studies have reported a decrease in BP after
PTX(5,12).Recently,Bollerslevetal.(12)havereported,
from a randomized study, declines in BP in both surgical
and observation groups of PHPT patients with mild
hypercalcemia.
To our knowledge, DTI has only been used once
before to evaluate cardiac function in PHPT patients.
Baycan et al. (26) reported small differences in some
variables of diastolic function in PHPT patients without
hypertension, diabetes mellitus, and coronary artery
disease. Similar to Baycan et al., we observed prolonged
IVRT in our study, but only in the male PHPT group in
comparison to female PHPT and healthy male controls.
We also found an inverse correlation between E/A ratio
and PTH. The clinical importance of these subtle
ﬁndings is unclear, but they may represent signs of
early diastolic dysfunction.
Available data on the extent and reversibility of
cardiovascular morbidity in PHPT and the coupling to
biochemical disturbances are conﬂicting (15).B a s e do n
a large population study, Kamycheva et al. (27) reported
serum PTH to be an independent predictor of coronary
heartdiseaseinbothsexes.Bergenfelzetal.(28)concluded
that a normal PTH level in PHPT is associated with a
milder form of disease and smaller adenomas, while
the calcium level did not reﬂect disease severity.
Recently, Walker et al. (29) have reported subclinical
carotid vascular manifestations in mild PHPT associated
with the extent of PTH elevation. The duration of the
disease is probably an important prognostic factor,
suggesting beneﬁts of early surgical cure of mild PHPT
before irreversible cardiovascular manifestations may
occur (5, 29).
To conclude, our results indicate that patients with
PHPT without cardiovascular risk factors have a
normal cardiac morphology and function. The BP and
the systolic velocities were marginally reduced after PTX
but reﬂected the values of the control group. Our
ﬁndings warrant further investigation of the clinical
and prognostic signiﬁcance of these possibly disease-
related inotropic effects.
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